Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Blodleukocytprofilering ved eosinofil type 2-astma: Indflydelse af systemisk IL-5-målretning

10. august 2026 opdateret af: Region Skane

The goal of this exploratory and observational prospective study is to study the composition and phenotypes of blood leukocytes collected from asthmatic patients before and after instantiated treatment with the interleukin-5 neutralizing antibody mepolizumab. Comparisons will be made to leukocyte profiles in patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Asthma is a chronic inflammatory and obstructive condition affecting the airways. The disease is commonly associated with elevated blood eosinophils and tissue eosinophilia. Many aspects of the pathophysiological mechanisms and clinical symptoms are controlled by conventional therapies such as inhaled corticosteroids (ICS) and long acting β2 agonists. However, some patients remain clinically uncontrolled and need additional treatment such as direct targeting of eosinophil granulocytes by neutralizing the eosinophil-promoting cytokine interleukin 5 (IL5). Mepolizumab is a humanized monoclonal IL-5 neutralizing antibody that is used to treat patients with moderate-severe eosinophilic asthma. While a marked reduction of eosinophils is a key effect of mepolizumab, the exact mechanism of action is unknown. Apart from basophils, that also express the receptor for IL-5, other leukocytes are likely to be indirectly affected by the suppressed eosinophilia. In addition, it is largely unknown to what extent the few eosinophils remaining after anti-IL5 treatment differ from pre-treatment eosinophils.

The present study is a prospective observational asthma study that aims to use microscopic analysis to investigate the composition and subtypes of blood leukocytes collected before and after instantiated mepolizumab treatment. Comparisons are made to patients already on mepolizumab treatment, asthma patients without any biological treatment, and non-diseased control subjects.

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

37

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Skåne County
      • Lund, Skåne County, Sverige, 22185
        • The Lung and Allergy Clinic, Skåne University Hospital (SUS)

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 80 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

All asthma patients will be recruited at the Department of Allergology and Lung Medicine, Skåne University Hospital (SUS), Lund, Sweden. Healthy control subjects are recruited by local advertisement.

Beskrivelse

Inclusion Criteria:

  • Clinical diagnosis of asthma (the asthma patient arms)
  • Eligible for Mepolizumab treatment as per the country-specific prescribing information (the arms with Mepolizumab)

Exclusion criteria:

  • Any diagnosed infection (all arms)
  • Previous history of lung disease, chronic inflammatory condition, atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling (Healthy non-asthma control subjects)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: CROSS_SECTIONAL

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Asthma patients initiating Mepolizumab treatment

Patients will be selected on the standard criteria used to select eligible asthma patients for mepolizumab treatment (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients may be included. Exclusion criteria: any infection

Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.

Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andre navne:
  • Mepolizumab (mærkenavn: Nucala)

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andre navne:
  • ICS og LABA
Asthma patients already on Mepolizumab treatment

Patients that have been selected and given Mepolizumab treatment for > 4 months according to standard eligible and treatment regimen criteria (i.e. patients with eosinophilic asthma that are not controlled by conventional high dose ICS and LABA etc). All eligible asthma patients that have been on Mepolizumab treatment for > 4 weeks will be included. Exclusion criteria: any infections

Mepolizumab is administered by subcutaneous injection with guideline recommended patient selection and dosing for treatment of eosinophilic asthma.

Accordingly, the Mepolizumab treatment is given as add-on therapy to standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andre navne:
  • Mepolizumab (mærkenavn: Nucala)

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andre navne:
  • ICS og LABA
Asthma patients without Mepolizumab treatment

Inclusion: Asthma patients without any biological (antibody-based) treatment but on routine ICS and LABA treatment as part of their normal care. Exclusion criteria are any infections

Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)

Andre navne:
  • ICS og LABA
Healthy non-asthmatic control subjects

Exclusion criteria: previous history of lung disease, chronic inflammatory condition, or atopy, or cardiovascular disease. Diagnosed or perceived infection within 3 weeks prior to blood sampling

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Blood Eosinophil Marker Expression
Tidsramme: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative analysis of low-intensity proMBP-positive eosinophil-lineage proxy cells in FFPE blood leukocyte pellet sections

Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood Basophil Marker Expression
Tidsramme: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative analysis of high-intensity proMBP-positive basophil-like cells in FFPE blood leukocyte pellet sections.

Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood Leukocyte Composition
Tidsramme: Baseline, Day 2, and Month 4 after mepolizumab initiation

Relative proportion of low-/mid-intensity proMBP-positive eosinophil-lineage proxy cells within the proMBP panel in FFPE blood leukocyte pellet sections

Baseline, Day 2, and Month 4 after mepolizumab initiation

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Blood T Lymphocyte Marker Expression
Tidsramme: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative CD4 Th-axis balance readout in FFPE blood leukocyte pellet sections, expressed as log2(GATA3/T-bet ratio).

Baseline, Day 2, and Month 4 after mepolizumab initiation
Change in Blood B Lymphocyte Marker Expression
Tidsramme: Baseline, Day 2, and Month 4 after mepolizumab initiation

Quantitative B-cell HLA-DR readout in FFPE blood leukocyte pellet sections, expressed as the percentage of HLA-DR-positive cells within the CD19/CD20-gated population.

Baseline, Day 2, and Month 4 after mepolizumab initiation
Leukocyte Total Cell Counts
Tidsramme: Baseline, Day 2, and Month 4 after mepolizumab initiation.

Routine clinical laboratory total leukocyte counts in peripheral blood

Baseline, Day 2, and Month 4 after mepolizumab initiation.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Forced Expiratory Volume in 1 Second (FEV1)
Tidsramme: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

Spirometry: Forced Expiratory Volume, 1s; (FEV1).

Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Change in Forced Vital Capacity (FVC)
Tidsramme: Change from baseline at 4 weeks, and 4 months after initiated biological treatment.

Spirometry: Forced Vital Capacity (FVC)

Change from baseline at 4 weeks, and 4 months after initiated biological treatment.
Change in Exhaled FeNo
Tidsramme: Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.

Fractional exhaled NO will be measured at multiple flows

Before and 1-3 days, 1 week, 4 weeks, and 4 months after initiated biological treatment.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Jonas Erjefält, Lund University Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. januar 2019

Primær færdiggørelse (Faktiske)

1. september 2025

Studieafslutning (Faktiske)

18. december 2025

Datoer for studieregistrering

Først indsendt

15. december 2022

Først indsendt, der opfyldte QC-kriterier

16. januar 2023

Først opslået (Faktiske)

19. januar 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

5. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. august 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 1072615

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .